Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Common Equity (2019 - 2025)

Historic Common Equity for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $315.3 million.

  • Allogene Therapeutics' Common Equity fell 3200.42% to $315.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $315.3 million, marking a year-over-year decrease of 3200.42%. This contributed to the annual value of $422.2 million for FY2024, which is 1758.07% down from last year.
  • As of Q3 2025, Allogene Therapeutics' Common Equity stood at $315.3 million, which was down 3200.42% from $344.6 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Common Equity peaked at $1.1 billion during Q1 2021, and registered a low of $315.3 million during Q3 2025.
  • Over the past 5 years, Allogene Therapeutics' median Common Equity value was $592.0 million (recorded in 2023), while the average stood at $646.6 million.
  • In the last 5 years, Allogene Therapeutics' Common Equity soared by 7638.01% in 2021 and then plummeted by 3309.99% in 2025.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Common Equity stood at $925.2 million in 2021, then fell by 27.92% to $666.9 million in 2022, then fell by 23.19% to $512.2 million in 2023, then dropped by 17.58% to $422.2 million in 2024, then decreased by 25.31% to $315.3 million in 2025.
  • Its last three reported values are $315.3 million in Q3 2025, $344.6 million for Q2 2025, and $385.4 million during Q1 2025.